Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
Beamion LUNG-2
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- NCT06151574 ↗
- Active, not recruiting
- Boehringer Ingelheim
- Standard
We haven't built an HCP commentary report on Beamion LUNG-2 (zongertinib) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Beamion LUNG-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| Podcasts | 3 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Lung Cancer, Non-squamous, Non-small Cell
- Interventions
- zongertinib; pembrolizumab; cisplatin; carboplatin; pemetrexed
- Arms
- Experimental treatment arm · Experimental
- Comparator arm · Active comparator
- Enrollment
- 428
- Primary outcomes
- Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent review
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 9, 2024
- Primary completion
- Dec 10, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06151574 · updated Oct 1, 2026
Publications
linked from the registry- Puri S, Ismaila N, Azar IH, Freeman-Daily J, Furuya N, Kuruvilla S, Roof L, Velazquez AI, Wang Y, Wheatley Price P, Leighl NB. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2. J Clin Oncol. 2026 Sep 10;44(26):e127-e139. doi: 10.1200/JCO-26-01479. Epub 2026 Jun 29. PubMed 42372216